These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 1838101)

  • 1. Informing the mammography coverage debate. Results of meta-analysis, computer modeling, and issue analysis.
    Simpson KN; Snyder LB
    Int J Technol Assess Health Care; 1991; 7(4):616-31. PubMed ID: 1838101
    [TBL] [Abstract][Full Text] [Related]  

  • 2. States enact mammography coverage laws.
    Moore KG
    Womens Health Issues; 1991; 1(2):102-8. PubMed ID: 1822368
    [No Abstract]   [Full Text] [Related]  

  • 3. Determining health insurance coverage of technology: problems and options.
    Greenberg B; Derzon RA
    Med Care; 1981 Oct; 19(10):967-78. PubMed ID: 6796788
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Breast cancer screening among women younger than age 50: a current assessment of the issues.
    Smith RA
    CA Cancer J Clin; 2000; 50(5):312-36. PubMed ID: 11075240
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The feasibility of breast cancer screening.
    Health Technol; 1987; 1(1):26-37. PubMed ID: 10311915
    [No Abstract]   [Full Text] [Related]  

  • 6. The scientific basis for coverage decisions by third-party payers.
    Towery OB; Perry S
    JAMA; 1981 Jan; 245(1):59-61. PubMed ID: 6776306
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Breast cancer. Selected legal issues.
    Wynstra NA
    Cancer; 1994 Jul; 74(1 Suppl):491-511. PubMed ID: 8004625
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Who should rightfully decide whether a medical treatment necessarily incurred should be excluded from coverage under a health insurance policy provision which excludes from coverage "experimental" medical treatments?
    Fisfis BA
    Spec Law Dig Health Care Law; 1994 Mar; (181):9-32. PubMed ID: 10133063
    [No Abstract]   [Full Text] [Related]  

  • 9. From principle to public policy: using cost-effectiveness analysis.
    Neumann PJ; Johannesson M
    Health Aff (Millwood); 1994; 13(3):206-14. PubMed ID: 7927151
    [No Abstract]   [Full Text] [Related]  

  • 10. Mammography: past--underused, present--underfinanced, future--unavailable?
    Weber ES
    Clin J Oncol Nurs; 2002; 6(3):123. PubMed ID: 11998598
    [No Abstract]   [Full Text] [Related]  

  • 11. Estimation of the Cost-Effectiveness of Breast Cancer Screening Using Mammography in Mexico Through a Simulation.
    Ulloa-Pérez E; Mohar-Betancourt A; Reynoso-Noverón N
    Rev Invest Clin; 2016; 68(4):184-91. PubMed ID: 27623037
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Civilian Health and Medical Program of the Uniformed Services (CHAMPUS); coverage of screening mammography and Papanicolaou (PAP) tests, certified marriage and family therapists, and requirements for coverage and reimbursement of services of physicians in teaching settings--Office of the Secretary, DoD. Final rule.
    Fed Regist; 1994 Feb; 59(35):8401-8. PubMed ID: 10133070
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The muddle over screening breast Ca.
    Thomas P
    Med World News; 1988 May; 29(9):34-6, 42, 47-8. PubMed ID: 10312486
    [No Abstract]   [Full Text] [Related]  

  • 14. Mammography screening under 50: a limited perspective on a multifaceted issue.
    Royak-Schaler R; Gallant SJ; Klabunde CN
    Womens Health; 1996; 2(4):243-9; discussion 261-6. PubMed ID: 9421559
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Consideration of insurance reimbursement for physical activity and exercise programs for patients with diabetes.
    Pahor M
    JAMA; 2011 May; 305(17):1808-9. PubMed ID: 21540427
    [No Abstract]   [Full Text] [Related]  

  • 16. Perceptions of insurance coverage for screening mammography among women in need of screening.
    McAlearney AS; Reeves KW; Tatum C; Paskett ED
    Cancer; 2005 Jun; 103(12):2473-80. PubMed ID: 15884097
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The medical device payment controversy rages on.
    Brown E
    Physician Exec; 1995 Nov; 21(11):40-1. PubMed ID: 10153735
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Review of medical technology policies shows need, opportunities for changes.
    Banta D
    Hospitals; 1982 Apr; 56(7):87-90. PubMed ID: 6800914
    [No Abstract]   [Full Text] [Related]  

  • 19. Economics and cost-effectiveness in evaluating the value of cardiovascular therapies. The value of cost-effectiveness analyses for reimbursement decisions: perspectives from Medicare.
    Sheingold SH
    Am Heart J; 1999 May; 137(5):S81-6. PubMed ID: 10220604
    [No Abstract]   [Full Text] [Related]  

  • 20. Coverage, technology assessment, and the courts.
    McGivney WT
    Physician Exec; 1991; 17(1):36-8. PubMed ID: 10110136
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.